Investment Theme
Digital Health
AI and digital solutions that address a clear clinical, workflow, or patient-adoption problem, evaluated past the label to what the software actually does.
The Space
Digital health is where the pitch is easiest to make sound impressive and hardest to verify — "AI-powered" describes almost nothing about whether a product actually improves an outcome or a workflow. ChaosBio reads past the label to the underlying evidence, the data the model was trained and validated on, and whether a clinician or patient would actually change behavior because of it.
The category spans clinical decision support, patient-facing tools, and workflow software for providers and health systems — each with a different bar for what "evidence" should mean.
Why It Matters
The gap between promising and investable.
A digital health company that cannot show its model or product working on real-world, out-of-sample data is making a claim, not demonstrating a result — and the difference matters enormously to whether it can raise a serious next round.
The strongest digital health founders can explain exactly what their tool changes for the end user, in plain terms, without leaning on the AI framing to do the explaining for them.
The ChaosBio Lens
What ChaosBio looks for.
Applied to every digital health opportunity ChaosBio reviews, alongside the general investment framework.
Evidence over label
What does the tool actually demonstrate, on what data, validated how — not what category it is marketed under?
Workflow or clinical fit
Does this solve a problem a clinician, patient, or health system feels acutely enough to change existing behavior?
Regulatory posture
Is there clarity on whether the product is a regulated medical device, clinical decision support, or wellness software — and has that been thought through rather than assumed?
Data and defensibility
What is the actual data advantage, and is it something a well-funded competitor could replicate in a year?
Related Reading
From the Journal.
See digital health opportunities as they come in.
Join the Investor Network for curated digital health and other early-stage life sciences opportunities, reviewed through the ChaosBio investment framework. Free, and no obligation to invest.